EDIT Stock Financial Analysis - Editas Medicine, Inc. (NasdaqGS) Stock

Overview

Editas Medicine, Inc., based in the United States, operates within the biotechnology sector and is notable for its pioneering efforts in gene editing technology. Specializing in the CRISPR/Cas9 and CRISPR/Cas12 systems, the company focuses on developing transformative gene-editing therapies to treat a diverse range of diseases with unmet medical needs. Key projects include a leading development program targeting Leber Congenital Amaurosis type 10 (LCA10), a severe genetic eye disorder, endeavoring to correct this mutation-driven ailment at the DNA level. Additionally, Editas Medicine sustains active research in exploring treatment options for other genetic conditions, including sickle cell disease and beta-thalassemia, signifying its strategic commitment to medical innovation and genetic disease treatment.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Editas Medicine, Inc. as of June 30, 2025 is 38.90 MM.
The operating income for Editas Medicine, Inc. as of June 30, 2025 is -160.80 MM.
The net income for Editas Medicine, Inc. as of June 30, 2025 is -236.86 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	38.90	-160.80	-236.86
2025-03-31	35.84	-207.24	-251.23
2024-12-31	32.31	-238.92	-237.09
2024-09-30	61.76	-228.52	-210.57
2024-06-30	67.03	-213.02	-193.45
2024-03-31	69.41	-185.21	-166.13
2023-12-31	78.12	-169.18	-153.22
2023-09-30	24.61	-208.66	-195.08
2023-06-30	19.32	-216.02	-205.79
2023-03-31	22.79	-226.16	-218.95
2022-12-31	19.71	-225.95	-220.43
2022-09-30	25.64	-204.11	-201.13
2022-06-30	31.80	-185.85	-184.49
2022-03-31	25.82	-187.01	-186.29
2021-12-31	25.54	-193.15	-192.50
2021-09-30	24.49	-217.41	-213.56
2021-06-30	81.14	-169.17	-166.66
2021-03-31	91.51	-145.11	-134.98
2020-12-31	90.73	-134.84	-115.98
2020-09-30	91.60	-108.39	-91.25

Income Statement: EPS

The earnings per share basic for Editas Medicine, Inc. as of June 30, 2025 is -2.85.
The earnings per share diluted for Editas Medicine, Inc. as of June 30, 2025 is -2.85.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-2.85	-2.85
2025-03-31	-3.04	-3.04
2024-12-31	-2.88
2024-09-30	-2.56	-2.56
2024-06-30	-2.36	-2.36
2024-03-31	-2.10	-2.10
2023-12-31	-2.02
2023-09-30	-2.68	-2.68
2023-06-30	-2.96	-2.96
2023-03-31	-3.18	-3.18
2022-12-31	-3.21
2022-09-30	-2.93	-2.93
2022-06-30	-2.70	-2.70
2022-03-31	-2.73	-2.73
2021-12-31	-2.85
2021-09-30	-3.23	-3.23
2021-06-30	-2.58	-2.58
2021-03-31	-2.20	-2.20
2020-12-31	-1.98
2020-09-30	-1.63	-1.62

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Editas Medicine, Inc. as of June 30, 2025 is -201.36 MM.
The cash from investing activities for Editas Medicine, Inc. as of June 30, 2025 is 213.97 MM.
The cash from financing activities for Editas Medicine, Inc. as of June 30, 2025 is 61.49 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-201.36	213.97	61.49
2025-03-31	-208.21	223.28	54.40
2024-12-31	-210.28	162.15	56.03
2024-09-30	-181.76	194.03	1.03
2024-06-30	-164.63	7.23	1.03
2024-03-31	-146.28	-31.74	118.23
2023-12-31	-132.18	-3.73	118.04
2023-09-30	-152.21	-94.10	118.14
2023-06-30	-164.76	97.95	118.22
2023-03-31	-163.89	80.96	1.07
2022-12-31	-177.35	114.07	1.28
2022-09-30	-169.66	118.76	1.72
2022-06-30	-162.44	-10.13	4.14
2022-03-31	-163.55	-1.34	20.85
2021-12-31	-163.80	-54.47	282.11
2021-09-30	-169.32	-140.52	290.15
2021-06-30	-183.34	-253.12	288.48
2021-03-31	-175.24	-183.74	482.55
2020-12-31	-179.84	-140.52	224.12
2020-09-30	-98.72	-23.81	299.59

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Editas Medicine, Inc. as of June 30, 2025 is 2.94.
The p/tbv for Editas Medicine, Inc. as of June 30, 2025 is 2.94.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		2.94	2.94
2025-03-31	-0.44	0.77	0.77
2024-12-31		0.56	0.56
2024-09-30	-1.48	1.23	1.23
2024-06-30	-2.35	1.32	1.32
2024-03-31		1.70	1.70
2023-12-31	-4.24	2.29	2.29
2023-09-30	-2.67	1.38	1.38
2023-06-30	-2.57	1.77	1.77
2023-03-31	-2.22	1.36
2022-12-31		1.44	1.44
2022-09-30		1.80	1.80
2022-06-30	-4.36	1.58	1.58
2022-03-31	-6.76	2.35	2.35
2021-12-31	-8.41	2.93	2.93
2021-09-30	-16.79	4.39	4.39
2021-06-30
2021-03-31	-6.78	2.32	2.32
2020-12-31	-7.31	2.16	2.16
2020-09-30	-9.19	1.90	1.90

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Editas Medicine, Inc. as of June 30, 2025 is -5.58.
The ebit (3y)/ev for Editas Medicine, Inc. as of June 30, 2025 is -4.81.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-5.58	-4.81
2025-03-31	8.52	7.45
2024-12-31	-65.28	-60.37
2024-09-30	-0.87	-0.89
2024-06-30	-0.52	-0.59
2024-03-31	-0.33	-0.40
2023-12-31	-0.26	-0.27
2023-09-30	-0.62	-0.56
2023-06-30	-0.50	-0.44
2023-03-31	-0.63	-0.52
2022-12-31	-0.52	-0.44
2022-09-30	-0.28	-0.24
2022-06-30	-0.31	-0.27
2022-03-31	-0.18	-0.14
2021-12-31	-0.14	-0.10
2021-09-30	-0.07	-0.05
2021-06-30
2021-03-31	-0.24	-0.23
2020-12-31	-0.16	-0.17
2020-09-30	-0.16	-0.20

Management Effectiveness

The roa for Editas Medicine, Inc. as of June 30, 2025 is -0.65.
The roe for Editas Medicine, Inc. as of June 30, 2025 is -1.08.
The roic for Editas Medicine, Inc. as of June 30, 2025 is -2.69.
The croic for Editas Medicine, Inc. as of June 30, 2025 is 0.74.
The ocroic for Editas Medicine, Inc. as of June 30, 2025 is -2.23.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.65	-1.08	-2.69	0.74	-2.23
2025-03-31	-0.54	-0.81	-1.40	0.05	-1.24
2024-12-31	-0.42	-0.60	-0.98	0.06	-0.85
2024-09-30	-0.38	-0.54	-0.71	-0.58	-0.61
2024-06-30	-0.36	-0.52	-0.51	-0.18	-0.45
2024-03-31	-0.30	-0.42	-0.40	-0.05	-0.34
2023-12-31	-0.37	-0.47	-0.49	-0.32	-0.39
2023-09-30	-0.35	-0.44	-0.47	0.12	-0.38
2023-06-30	-0.38	-0.47	-0.47	0.12	-0.38
2023-03-31	-0.35	-0.43	-0.62	-0.23	-0.46
2022-12-31	-0.28	-0.33	-0.46	-0.11	-0.39
2022-09-30	-0.26	-0.30	-0.46	-0.11	-0.39
2022-06-30	-0.25	-0.29	-0.38	-0.35	-0.33
2022-03-31	-0.25	-0.49	-0.35	-0.27	-0.31
2021-12-31	-0.37	-0.48	-0.33	0.11	-0.26
2021-09-30	-0.36	-0.39	-0.33	-0.03	-0.27
2021-06-30	-0.25	-0.39	-0.25	-0.22	-0.27
2021-03-31	-0.29	-0.51	-0.20	0.19	-0.41
2020-12-31	-0.23	-0.44	-0.25	-0.21	-0.38
2020-09-30	-0.25	-0.43	-0.20	0.39	-0.22

Gross Margins

The gross margin for Editas Medicine, Inc. as of June 30, 2025 is -3.22.
The net margin for Editas Medicine, Inc. as of June 30, 2025 is -7.01.
The operating margin for Editas Medicine, Inc. as of June 30, 2025 is -5.78.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-3.22	-7.01	-5.78
2025-03-31	-5.17	-7.34	-7.39
2024-12-31	-2.57	-3.41	-3.70
2024-09-30	-0.72	-2.89	-3.18
2024-06-30	-1.06	-2.39	-2.67
2024-03-31	-1.27	-1.96	-2.17
2023-12-31	-5.51	-7.93	-8.48
2023-09-30	-4.07	-10.65	-11.18
2023-06-30	-5.10	-10.65	-11.18
2023-03-31	-7.88	-9.61	-9.92
2022-12-31	-5.26	-7.84	-7.96
2022-09-30	-3.67	-7.84	-7.96
2022-06-30	-4.37	-5.80	-5.84
2022-03-31	-4.58	-7.22	-7.24
2021-12-31	-5.80	-7.54	-7.56
2021-09-30	-1.11	-8.72	-8.88
2021-06-30	-1.11	-2.05	-2.08
2021-03-31	-0.81	-1.48	-1.59
2020-12-31		-1.28	-1.49
2020-09-30	-0.43	-1.00	-1.18